Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Objectives Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. In real-world clinical practice, patients would turn to plasma genotyping or take osimertinib blindly after CN...

Full description

Bibliographic Details
Main Authors:	Jun Liao MD, Yihua Huang MD, Jiadi Gan MD, Lanlan Pang MD, Wael A. S. Ali MD, Yunpeng Yang MD, PhD, Likun Chen MD, PhD, Li Zhang MD, PhD, Wenfeng Fang MD, PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-02-01
Series:	Cancer Control
Online Access:	https://doi.org/10.1177/10732748221081360

Similar Items

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
by: Sho Takuma, MD, et al.
Published: (2022-01-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
by: Naoki Haratake, MD, PhD, et al.
Published: (2020-11-01)

Simultaneous intracranial and extracranial vertebral artery dissections: a case report
by: Hideki Endo, MD, PhD, et al.
Published: (2023-08-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
by: Bin-Chi Liao, MD, et al.
Published: (2021-01-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Endovascular treatment of patient with multiple extracranial large vessel stenosis and coexistent unruptured wide-neck intracranial aneurysm using a WEB device and Szabo-technique
by: Yurii Cherednychenko, MD, PhD, et al.
Published: (2020-12-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report
by: Shota Takahashi, MD, et al.
Published: (2024-02-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Management strategy for extracranial carotid artery aneurysms
by: Eol Choi, MD, PhD, et al.
Published: (2022-05-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
by: Anita J.W. M. Brouns, MD, et al.
Published: (2023-05-01)

A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood
by: Shamini Selvarajah, PhD, et al.
Published: (2021-08-01)

Pediatric Cystinuria Patient With Novel Mutation in
by: Yoshitaka Watanabe MD, PhD, et al.
Published: (2019-07-01)

Extracranial carotid artery aneurysm with myeloproliferative neoplastic cell invasion
by: Shotaro Ogawa, MD, et al.
Published: (2020-06-01)

Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib
by: Carlos Henrique A. Teixeira, MD, et al.
Published: (2020-09-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
by: Andrew J. Piper-Vallillo, MD, et al.
Published: (2020-03-01)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

Locked-in syndrome caused by extracranial and intracranial takayasu arteritis: A rare case report and radiological findings
by: Muh. Wildan Yahya, MD, et al.
Published: (2023-09-01)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01)

Osimertinib-Induced Cardiotoxicity
by: Kartik Anand, MD, et al.
Published: (2019-12-01)

Variable phenotype expression with a frameshift mutation of the cardiac sodium channel gene SCN5A
by: Hiroshi Kawakami, MD, et al.
Published: (2013-10-01)

A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
by: Kazushige Wakuda, MD, et al.
Published: (2023-12-01)

Glioblastoma with extracranial parotid, lymph node, and pulmonary metastases: a case report
by: Jeroen Swinnen, MD, et al.
Published: (2019-11-01)

Development and Validation of Machine Learning Models to Predict Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Multi-Center Retrospective Radiomics Study
by: Yafeng Liu MD, et al.
Published: (2022-04-01)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
by: Marina C. Garassino, MD, et al.
Published: (2023-01-01)

Identification of Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
by: Tekincan Çağrı Aktaş MD, PhD, et al.
Published: (2023-11-01)

Intracranial chondrosarcoma located in the region of the posterior clinoid process: a case report
by: Tomomichi Kayahara, MD, PhD, et al.
Published: (2022-01-01)

A novel ACTC1 mutation in a young boy with left ventricular noncompaction and arrhythmias
by: Yoko Yoshida, MD, et al.
Published: (2016-01-01)

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
by: Hongsik Kim MD, et al.
Published: (2021-12-01)

Evaluation of Phosphorylated Urinary Na-Cl Cotransporter Is Potentially Useful in a Patient With Pseudohypoaldosteronism Type II due to Mutation in
by: Keiko Nagahara MD, PhD, et al.
Published: (2014-09-01)